Healthcare

Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales

Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with…

Pediatrix Medical Group Returns to Full-Year Profitability Following Practice Portfolio Realignment

Pediatrix Medical Group (NYSE: MD), the physician services provider reports net income of $165.4 million for 2025 as it completes…

Prenetics Reports Record Q4 and FY2025 Revenue; Guides for 2026 Growth

Prenetics Global Limited (NASDAQ: PRE), a health sciences company, reported record financial results for the fourth quarter and full fiscal…

Insulet Corporation Reports 31% Annual Revenue Growth; Authorizes $350 Million Repurchase Increase

The global medical technology leader exceeded 2025 financial targets behind a 44% surge in international sales and the expansion of…

Charles River Laboratories (CRL) Q4 revenue, adjusted earnings top expectations

Charles River Laboratories International, Inc. (NYSE: CRL), a provider of products and services for pharma companies to accelerate drug discovery…

AtriCure reports surprise Q4 profit on strong worldwide revenue growth

Shares of AtriCure, Inc. (Nasdaq: ATRC) rose 6.4% to $34.12 in Wednesday morning trading after the medical device maker reported…

Beta Bionics Shares Edge Higher After Q4 Revenue Jumps 57%, Full-Year Sales Top $100 Million

Shares of Beta Bionics, Inc. (Nasdaq: BBNX) were trading modestly higher in late morning U.S. trading on Wednesday, up about…

cbdMD reports narrowed Q1 net loss, issues going-concern warning

Shares of cbdMD, Inc. (NYSE YCBD) rose 10.72% to $0.78 in Tuesday afternoon trading following the release of its fiscal…

Genmab Q4 2025 Earnings Report: Innovation Push Drives Profit Surge

Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company's improved operational execution. Total revenue reached $3.72…

WAY Shares Close at $24.29 After Waystar Reports Q4 2025 Results

Waystar Holding Corp (Nasdaq: WAY) shares closed at $24.29 at the latest U.S. market close following the company’s fourth-quarter and…